Commentary on Landry et al.: "Propentofylline, a CNS glial modulator, does not decrease pain in post-herpetic neuralgia patients: in vitro evidence for differential responses in human and rodent microglia and macrophages"

Watkins, L.Hutchinson, M.Johnson, K.2012-11-202012-11-202012Experimental Neurology, 2012; 234(2):351-3530014-48861090-2430http://hdl.handle.net/2440/74366Landry et al. provide a 2-part study. Part 1 reports the failure of propentofylline to show reduced pain in patients with post-herpetic neuralgia. Part 2 reports cell culture results for macrophages and microglia. Comments regarding each are provided below. Such significant concepts to the field of translational validity of glial cell modulation and related pharmacotherapy as reported in Landry et al. warrant higher standards of study design and data presentation than their paper affords.en© 2012 Elsevier Inc. All rights reservedFETALNeuralgiaPostherpetic - drug therapyMacrophages - drug effectsBRAINMicroglia - drug effectsCommentary on Landry et al.: "Propentofylline, a CNS glial modulator, does not decrease pain in post-herpetic neuralgia patients: in vitro evidence for differential responses in human and rodent microglia and macrophages"Journal article002011971510.1016/j.expneurol.2012.01.0060003019949000112-s2.0-8485815675924231Hutchinson, M. [0000-0003-2154-5950]